journal article·2026-05-13

Mannose-Conjugation Resolves the Efficiency–Toxicity Trade-Off in Amine Functionalized Silica Nanocarriers via Tunable pH-Responsive Drug Release

Sumiya Iqbal, Shaista Ilyas, Liudmila Lobastova, Duc Pham, Hans A. Schlößer, Phuong-Hien Nguyen, Kerstin Wennhold, Sanjay Mathur

ACS Applied Materials & Interfaces· Volume 18· Issue 18
Publisher page

Abstract

Mesoporous silica nanoparticles (mSiO 2 –NPs) are efficient drug delivery vehicles, yet their surface chemistry critically dictates payload uptake, therapeutic efficiency, and biocompatibility. Conventional organic coatings on the surface, such as polyethylenimine (PEI), improve drug loading capacity but substantiate cytotoxicity, while inorganic coatings/surface functionalization (e.g., (3-aminopropyl)trimethoxysilane (APTMS)) grafting reduces toxicity but offers uncontrolled drug release. Here, we present the first systematic comparison of APTMS- and PEI-functionalized mSiO 2, with and without mannose conjugation, to establish how sequential surface modification governs nicotinic acid (NA) loading, release kinetics, and cellular response. Using NA as a model drug, PEI-coated carriers achieved the highest loading (DEE = 83%) and sustained, pH-responsive release (41% in 24 h at pH 5.5) but displayed pronounced cytotoxicity in breast cancer cells (MCF-7) and peripheral blood mononuclear cells (PBMCs). Mannose conjugation substantially reduced this toxicity, while maintaining drug loading efficiency and enhancing cellular uptake in both epithelial and immune cell cultures. Notably, mannose-functionalized PEI carriers exhibited targeted, stimulus-sensitive release and selective enrichment in monocyte subsets without inducing immune activation, consistent with uptake mediated by carbohydrate-binding receptors confirmed via confocal colocalization analysis. These findings establish mannose coating as an effective strategy to reconcile efficiency and safety in amine-functionalized silica nanocarriers, providing a practical design principle for targeted and biocompatible drug delivery systems.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Inorganic and Materials Chemistry, University of Cologne, Greinstr. 6, 50939 Cologne, Germany

Center for Molecular Medicine Cologne (CMMC), University of Cologne, Robert-Koch-Str. 21, 50931 Cologne, Germany

Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine; Center for Molecular Medicine Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany

Center for Molecular Medicine Cologne, Faculty of Medicine of the University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany

Department of General, Visceral, Cancer and Transplantation Surgery

University of Cologne, Faculty of Medicine and University Hospital Cologne

Funding

Deutscher Akademischer Austauschdienst

References (66)

Show source-provided references
1. 10.1038/s41423-024-01216-z10.1038/s41423-024-01216-z ↗
2. 10.1186/s13046-025-03377-910.1186/s13046-025-03377-9 ↗
3. 10.1038/s41423-024-01232-z10.1038/s41423-024-01232-z ↗
4. 10.1021/am508404t10.1021/am508404t ↗
5. 10.1038/s41598-018-19521-910.1038/s41598-018-19521-9 ↗
6. 10.3390/antiox1406073510.3390/antiox14060735 ↗
7. 10.1038/s41698-024-00522-z10.1038/s41698-024-00522-z ↗
8. 10.1007/s00262-023-03406-610.1007/s00262-023-03406-6 ↗
9. 10.1038/s41419-024-06616-710.1038/s41419-024-06616-7 ↗
10. 10.3389/fbioe.2023.124842110.3389/fbioe.2023.1248421 ↗
11. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
12. 10.1021/jacs.2c1075710.1021/jacs.2c10757 ↗
13. 10.1039/D1RA04293A10.1039/D1RA04293A ↗
14. 10.1021/acs.biomac.2c0099310.1021/acs.biomac.2c00993 ↗
15. 10.1021/acsabm.3c0098510.1021/acsabm.3c00985 ↗
16. 10.1038/s41536-025-00403-410.1038/s41536-025-00403-4 ↗
17. 10.1038/s41392-025-02124-y10.1038/s41392-025-02124-y ↗
18. 10.1039/D3MA00820G10.1039/D3MA00820G ↗
19. 10.1021/acsnano.4c0881110.1021/acsnano.4c08811 ↗
20. 10.3390/ijms2503137010.3390/ijms25031370 ↗
21. 10.1186/s12885-022-09612-210.1186/s12885-022-09612-2 ↗
22. 10.3390/pharmaceutics1409197610.3390/pharmaceutics14091976 ↗
23. 10.1038/s41392-023-01654-710.1038/s41392-023-01654-7 ↗
24. 10.3390/biom1409105710.3390/biom14091057 ↗
25. 10.3389/fchem.2022.93158410.3389/fchem.2022.931584 ↗
26. 10.1016/j.sajce.2024.08.01310.1016/j.sajce.2024.08.013 ↗
27. 10.1002/adfm.20190263410.1002/adfm.201902634 ↗
28. 10.1038/s41598-022-25095-410.1038/s41598-022-25095-4 ↗
29. 10.1039/D4MA01267D10.1039/D4MA01267D ↗
30. 10.1039/D5RA00948K10.1039/D5RA00948K ↗
31. 10.1039/D5PM00066A10.1039/D5PM00066A ↗
32. 10.1038/s41578-022-00426-z10.1038/s41578-022-00426-z ↗
33. 10.1016/j.omtn.2017.08.01310.1016/j.omtn.2017.08.013 ↗
34. 10.3390/cancers1311263110.3390/cancers13112631 ↗
35. 10.1038/s41598-018-23078-y10.1038/s41598-018-23078-y ↗
36. 10.1021/acs.macromol.3c0122310.1021/acs.macromol.3c01223 ↗
37. 10.1021/acsabm.5c0039210.1021/acsabm.5c00392 ↗
38. 10.1021/acsnano.8b0515110.1021/acsnano.8b05151 ↗
39. 10.1002/slct.20240045010.1002/slct.202400450 ↗
40. 10.1021/nn900918w10.1021/nn900918w ↗
41. 10.1002/smsc.20240008410.1002/smsc.202400084 ↗
42. 10.1021/acsami.2c1809010.1021/acsami.2c18090 ↗
43. 10.1039/D3NA00031A10.1039/D3NA00031A ↗
44. 10.1021/accountsmr.0c0002810.1021/accountsmr.0c00028 ↗
45. 10.1039/D4NR04572F10.1039/D4NR04572F ↗
46. 10.1038/s41598-021-02699-w10.1038/s41598-021-02699-w ↗
47. 10.1038/s41598-023-50021-710.1038/s41598-023-50021-7 ↗
48. 10.1038/s41598-024-84131-710.1038/s41598-024-84131-7 ↗
49. 10.1039/D2RA00347C10.1039/D2RA00347C ↗
50. 10.1021/acs.langmuir.0c0282010.1021/acs.langmuir.0c02820 ↗
51. 10.1021/acsomega.2c0433110.1021/acsomega.2c04331 ↗
52. 10.3390/foods1411188110.3390/foods14111881 ↗
53. 10.1021/acsami.3c1057910.1021/acsami.3c10579 ↗
54. 10.3389/fnano.2025.156418810.3389/fnano.2025.1564188 ↗
55. 10.3390/molecules2719643910.3390/molecules27196439 ↗
56. 10.1152/physrev.00009.202210.1152/physrev.00009.2022 ↗
57. 10.1038/s41598-021-98611-710.1038/s41598-021-98611-7 ↗
58. 10.1371/journal.pone.024045510.1371/journal.pone.0240455 ↗
59. 10.18632/oncotarget.2323810.18632/oncotarget.23238 ↗
60. 10.1016/j.cmet.2021.09.00210.1016/j.cmet.2021.09.002 ↗
61. 10.1021/acsbiomaterials.3c0021810.1021/acsbiomaterials.3c00218 ↗
62. 10.1039/D3TB00607G10.1039/D3TB00607G ↗
63. 10.2217/nnm-2018-007610.2217/nnm-2018-0076 ↗
64. 10.1002/eji.183027094110.1002/eji.1830270941 ↗
65. 10.1155/2013/86971810.1155/2013/869718 ↗
66. 10.1039/D4NR01420K10.1039/D4NR01420K ↗